TB-500
Healing & Repairaka Thymosin beta-4 fragment · TB500 · LKKTETQ fragment
Overview
TB-500 — as flagged by the FDA — refers specifically to the thymosin beta-4 fragment LKKTETQ, not full-length thymosin beta-4. The two are frequently conflated in marketing material, but the FDA states it lacks human exposure data for fragment-containing drug products. No approved human medicine exists.
Mechanism
The repair claims for TB-500 are largely extrapolated from full thymosin beta-4 biology, which includes G-actin binding, cell migration, angiogenesis, anti-inflammatory effects, and accelerated wound healing in animal and tissue-repair models. Fragment-specific human efficacy evidence is sparse. Public regulatory records do not treat the fragment as a marketed approved medicine, and FDA explicitly states it lacks important information about whether the fragment would cause harm if administered to humans.